Related Experiment Videos
Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants
N V Subhedar1, S W Ryan, N J Shaw
1Institute of Child Health, University of Liverpool.
Insights
Inhaled nitric oxide (NO) and dexamethasone did not reduce chronic lung disease (CLD) or death in high-risk preterm infants. This study found no significant benefit from these treatments initiated 96 hours after birth.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Critical Care
Background:
- Chronic lung disease (CLD) remains a significant concern for high-risk preterm infants.
- Early interventions are crucial to improve outcomes in vulnerable neonates.
Purpose of the Study:
- To evaluate the efficacy of inhaled nitric oxide (NO) and/or intravenous dexamethasone in preventing CLD and/or death in preterm infants.
- To assess the combined and individual effects of NO and dexamethasone treatments.
Main Methods:
- A factorial design randomized infants below 32 weeks gestation at high risk for CLD.
- Treatment groups included inhaled NO, intravenous dexamethasone, both, or conventional management.
- Infants were assessed for CLD and/or death before hospital discharge.
Main Results:
- No significant difference in CLD or death incidence was observed between infants treated with inhaled NO and controls (RR 1.05).
- Dexamethasone treatment also showed no significant reduction in CLD or death compared to controls (RR 0.95).
- The combined therapy group also did not demonstrate a statistically significant benefit.
Conclusions:
- Initiating inhaled nitric oxide or dexamethasone treatment at 96 hours of age did not prevent CLD or death in high-risk preterm infants.
- These findings suggest that the timing and specific agents may not be effective for this patient population.
- Further research may be needed to explore alternative therapeutic strategies or different treatment windows.
Aim:
To determine whether treatment with inhaled nitric oxide (NO) and/or dexamethasone reduces the incidence of chronic lung disease (CLD) and/or death in high risk preterm infants.
Methods:
Infants below 32 weeks of gestation were recruited at 96 hours of age if they were deemed to be at high risk of developing CLD. Infants were randomly assigned to one of four treatment groups using a factorial design: (1) 5-20 parts per million inhaled NO for 72 hours; (2) 0.5-1 mg/kg/day intravenous dexamethasone for 6 days; (3) both drugs together; (4) continued conventional management.
Results:
Forty two infants were randomised: 10 infants received inhaled NO alone; 11 dexamethasone alone; 10 both treatments; and 11 neither treatment. There was no difference in the combined incidence of CLD and/or death before discharge from hospital between either infants treated with inhaled NO and controls (RR 1.05, 95% CI 0.84-1.25), or those treated with dexamethasone and controls (RR 0.95, 95% CI 0.79-1.18).
Conclusions:
At 96 hours of age, neither treatment with inhaled NO nor dexamethasone prevented CLD or death.